With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback